Literature DB >> 8401098

Costs and cost-minimisation analysis.

R Robinson1.   

Abstract

Whatever kind of economic evaluation you plan to undertake, the costs must be assessed. In health care these are first of all divided into costs borne by the NHS (like drugs), by patients and their families (like travel), and by the rest of society (like health education). Next the costs have to be valued in monetary terms; direct costs, like wages, pose little problem, but indirect costs (like time spent in hospital) have to have values imputed to them. And that is not all: costs must be further subdivided into average, marginal, and joint costs, which help decisions on how much of a service should be provided. Capital costs (investments in plant, buildings, and machinery) are also important, as are discounting and inflation. In this second article in the series Ray Robinson defines the types of costs, their measurement, and how they should be valued in monetary terms.

Entities:  

Mesh:

Year:  1993        PMID: 8401098      PMCID: PMC1678700          DOI: 10.1136/bmj.307.6906.726

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  1 in total

1.  Cost-effectiveness of antihyperlipemic therapy in the prevention of coronary heart disease. The case of cholestyramine.

Authors:  G Oster; A M Epstein
Journal:  JAMA       Date:  1987-11-06       Impact factor: 56.272

  1 in total
  28 in total

Review 1.  Economic evaluation of pharmacy services--fact or fiction?

Authors:  B George; J Silcock
Journal:  Pharm World Sci       Date:  1999-08

2.  Health economic evaluation.

Authors:  A Shiell; C Donaldson; C Mitton; G Currie
Journal:  J Epidemiol Community Health       Date:  2002-02       Impact factor: 3.710

Review 3.  Economic Notes: opportunity cost.

Authors:  S Palmer; J Raftery
Journal:  BMJ       Date:  1999-06-05

4.  Pharmacoeconomic aspects in the treatment of curable and incurable cancer.

Authors:  V Jønsson; S R Clausen; M M Hansen
Journal:  Pharmacoeconomics       Date:  1995-10       Impact factor: 4.981

5.  DRG-based cost minimization models: applications in a hospital environment.

Authors:  Sakesun Suthummanon; Vincent K Omachonu
Journal:  Health Care Manag Sci       Date:  2004-08

6.  Is day care equivalent to inpatient care for active rheumatoid arthritis? Randomised controlled clinical and economic evaluation.

Authors:  C M Lambert; N P Hurst; J F Forbes; A Lochhead; M Macleod; G Nuki
Journal:  BMJ       Date:  1998-03-28

7.  Evidence-Based Decision Making 3: Health Technology Assessment.

Authors:  Daria O'Reilly; Richard Audas; Kaitryn Campbell; Meredith Vanstone; James M Bowen; Lisa Schwartz; Nazila Assasi; Ron Goeree
Journal:  Methods Mol Biol       Date:  2021

Review 8.  Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF): an appraisal of its pharmacoeconomic status in neutropenia associated with chemotherapy and autologous bone marrow transplant.

Authors:  K L Goa; H M Bryson
Journal:  Pharmacoeconomics       Date:  1994-01       Impact factor: 4.981

9.  Cost minimization using an artificial neural network sleep apnea prediction tool for sleep studies.

Authors:  Rahel A Teferra; Brydon J B Grant; Jesse W Mindel; Tauseef A Siddiqi; Imran H Iftikhar; Fatima Ajaz; Jose P Aliling; Meena S Khan; Stephen P Hoffmann; Ulysses J Magalang
Journal:  Ann Am Thorac Soc       Date:  2014-09

Review 10.  Health economics and cost-effectiveness research with special reference to hemato-oncology.

Authors:  Rajat Kumar
Journal:  Med J Armed Forces India       Date:  2013-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.